Description
Dutasteride Pharmacological action
Product for the treatment of benign prostatic hyperplasia. Inhibits the activity of 5? -reductase isoenzymes of types 1 and 2, which are responsible for converting testosterone into 5? -dihydrotestosterone. Dihydrotestosterone is the main androgen responsible for glandular hyperplasia of the prostate.
The maximum effect of dutasteride on the reduction of dihydrotestosterone concentrations is dose-dependent and is observed 1-2 weeks after the beginning of treatment. After 1 and 2 weeks of dutasteride therapy at a dose of 0.5 mg/day the average value of serum dihydrotestosterone concentrations is reduced by 85% and 90%.
Dutasteride helps to reduce the size of the prostate gland, improves urination and reduces the risk of acute urinary retention and the need for surgical treatment.
Indications
Treatment and prevention of the progression of benign prostatic hyperplasia.
Contraindications
-Hypersensitivity to dutasteride and other 5a-reductase inhibitors;
-It is contraindicated in women and children.
Directions for use
- The route of administration and dosing regimen of a particular drug depend on its formulation and other factors. The optimal dosing regimen is determined by the physician. It is necessary to strictly follow the compliance of the used dosage form of a particular drug with the indications for use and the dosing regimen.
- For adult men, including elderly patients, the recommended dosage for oral administration is 500 mcg 1 time per day. The treatment should be continued for at least 6 months.
